Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Abstract Background Anaplastic thyroid cancer (ATC) is one of the most aggressive malignancies, representing less than 5% of all thyroid carcinomas. Τhe median survival is limited to months due to the resistance of ATC to surgery, radioiodine therapy, radiotherapy and chemotherapy. This review will...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-03-01
|
| Series: | Thyroid Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13044-023-00147-7 |